These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 10837594)

  • 1. Ligand-targeted liposomes.
    Willis M; Forssen E
    Adv Drug Deliv Rev; 1998 Feb; 29(3):249-271. PubMed ID: 10837594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
    Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
    J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
    Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
    Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of liposomal formulations for cell targeting.
    Nogueira E; Gomes AC; Preto A; Cavaco-Paulo A
    Colloids Surf B Biointerfaces; 2015 Dec; 136():514-26. PubMed ID: 26454541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery.
    Vyas SP; Sihorkar V
    Adv Drug Deliv Rev; 2000 Sep; 43(2-3):101-64. PubMed ID: 10967224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice?
    Fathi S; Oyelere AK
    Future Med Chem; 2016 Nov; 8(17):2091-2112. PubMed ID: 27774793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends and developments in liposome drug delivery systems.
    Lian T; Ho RJ
    J Pharm Sci; 2001 Jun; 90(6):667-80. PubMed ID: 11357170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels.
    Rait AS; Pirollo KF; Xiang L; Ulick D; Chang EH
    Mol Med; 2002 Aug; 8(8):475-86. PubMed ID: 12435858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-targeted delivery for highly potent drugs.
    Bardania H; Tarvirdipour S; Dorkoosh F
    Artif Cells Nanomed Biotechnol; 2017 Dec; 45(8):1478-1489. PubMed ID: 28278584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers.
    Ranade VV
    J Clin Pharmacol; 1989 Aug; 29(8):685-94. PubMed ID: 2674208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Targeted-liposome Delivery System of Antitumor Drugs.
    Wu WD; Yi XL; Jiang LX; Li YZ; Gao J; Zeng Y; Yi RD; Dai LP; Li W; Ci XY; Si DY; Liu CX
    Curr Drug Metab; 2015; 16(10):894-910. PubMed ID: 26652257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
    Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
    J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin Targeting and Toxicological Assessment of Peptide-Conjugated Liposome Delivery Systems to Activated Endothelial Cells.
    Kermanizadeh A; Villadsen K; Østrem RG; Jensen KJ; Møller P; Loft S
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):380-389. PubMed ID: 27767251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-targeted liposome design: challenges and fundamental considerations.
    Noble GT; Stefanick JF; Ashley JD; Kiziltepe T; Bilgicer B
    Trends Biotechnol; 2014 Jan; 32(1):32-45. PubMed ID: 24210498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
    Yang Y; Yang Y; Xie X; Wang Z; Gong W; Zhang H; Li Y; Yu F; Li Z; Mei X
    Biomaterials; 2015 Apr; 48():84-96. PubMed ID: 25701034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomes for brain delivery.
    Lai F; Fadda AM; Sinico C
    Expert Opin Drug Deliv; 2013 Jul; 10(7):1003-22. PubMed ID: 23373728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells.
    Matthay KK; Abai AM; Cobb S; Hong K; Papahadjopoulos D; Straubinger RM
    Cancer Res; 1989 Sep; 49(17):4879-86. PubMed ID: 2788031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.